Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study is testing Orca-T — a specially engineered stem cell transplant product designed to reduce dangerous post-transplant immune complications — in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are not fit enough for a full-intensity bone marrow transplant. **You may be eligible if...** - You are 18 or older and have AML in remission or MDS with less than 10% blasts in the bone marrow - You are not eligible for a fully intensive bone marrow transplant - You have an available matched stem cell donor (8 out of 8 HLA match) - Your heart, lung, liver, and kidney function are adequate **You may NOT be eligible if...** - You have had a previous stem cell transplant - You are currently on immune-suppressing medications (low-dose topical steroids are okay) - You have active uncontrolled infections - You are HIV positive, have hepatitis B surface antigen, or have active hepatitis C - You have known allergy to tacrolimus (an anti-rejection drug) or to iron dextran - You are pregnant or breastfeeding - You have a concurrent active malignancy within the past year (except minor skin cancers) Talk to your doctor to see if this trial is right for you.